Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate

Benzinga Newsdesk www.benzinga.com Negative 97.4%

Neg 97.4% Neu 0% Pos 0%

Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.